HLB prepares US launch of bile duct cancer drug after liver cancer drug, presenting clinical results at ESMO
Predicted impact: Low
Drug launch preparation and conference data; no revenue size or approval event given.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.